Biotech Stocks TOI, IKT, ANRO, ELV, PRVA Hit 52-Week Highs on Key Catalysts

EarningsCorporate Action
โดย RTTNews·Read original
Summary · why it matters

Several biotech stocks reached 52-week highs on July 14, 2026, driven by capital-raising efforts and business expansions. The Oncology Institute hit $6.66 after repaying an $86 million convertible note and projecting full-year 2026 revenue of $630 million to $650 million. Inhibikase Therapeutics rose over 5% to $2.36 following a $50 million at-the-market share sale to fund its Phase 3 trial for pulmonary arterial hypertension drug IKT-001. Alto Neuroscience reached $28.85 after pricing a $100 million direct offering to advance its lead depression candidate ALTO-207 toward Phase 3. Elevance Health touched $434.38, supported by an estimated 2026 adjusted EPS of at least $26.75 and a consumer base of approximately 105 million. Privia Health Group climbed to $28.30, forecasting 2026 GAAP revenue of $2.35 billion to $2.45 billion, up from $2.12 billion in 2025.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 2 stocks
Health Care▲ · 2 stocks
Elevance Health Inc
ELV
▲ PositiveCapitalrelevance

Estimated 2026 adjusted EPS of at least $26.75 and 105M consumer base.

Others▲ · 1 stocks
© 2026 MarketDXNews